BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BIOHEART INC.

Bioheart, Inc.Bioheart, Inc. is focused on the discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases such as congestive heart failure (“CHF”) secondary to myocardial infarction (“MI”) and cardiovascular electrical abnormalities. The Company believes that its products hold the potential to revolutionize the treatment of cardiovascular diseases and become a new standard of care by offering treatments that improve cardiac function, are more cost-effective and are lower-risk than the current alternatives, which include heart transplantation, biventricular pacing, ventricular assist devices and certain drug therapies.
Bioheart’s initial patient-derived (“autologous”) cellular-based implant technology (MyoCell™) harvests specially selected cells from a patient’s own thigh muscle and utilizes that raw material to produce uniquely composed implants that are placed into the heart either percutaneously (via cardiac catheter) or surgically. The MyoCell therapy is designed to regenerate infarcted, scarred or non-functioning myocardial tissue into functioning muscle that contributes to increased global cardiac output and slows down the progression of CHF. The MyoCell product has also demonstrated the ability to positively impact the heart muscle remodeling process. It is expected that the market for MyoCell will include anyone who has suffered from a heart attack (myocardial infarction).


Contact Details:
13794 NW 4th Street, Suite 212
Sunrise
Florida
33325
United States of America
Tel:954-835-1500
Fax:954-845-9976
Email:hleonhardt@aol.com
WWW:

www.bioheartinc.com/




Loading...

BioNews Results for BIOHEART INC.:

Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cell
Pharma Live:  Oct 1 2008 8:39AM Matching: bioheart inc
Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cell
Yahoo!:  Sep 30 2008 3:39PM Matching: bioheart inc
Research and Markets: Learn From the Lessons Learned From the Current Crop of Biotech Startups
SmartBrief:  Sep 25 2008 5:27PM Matching: bioheart inc
Research and Markets: Learn From the Lessons Learned From the Current Crop of Biotech Startups
Business Wire via Yahoo!:  Sep 22 2008 9:19AM Matching: bioheart inc
Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
Montana's News Station:  Sep 19 2008 7:54PM Matching: bioheart inc
Promote your company here: BioNewsCast - Press Release Distribution

View more BIOHEART INC. news.

BIOHEART INC. Patents:

US Patent No.Title
7341062 Method of providing a dynamic cellular cardiac support
6988004 Method for inducing angiogenesis by electrical stimulation of muscles

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 228 times since April 2007, the link to the organisation's website has been followed 37 times

Recent Search Terms used to find this page: bioheart | .

Search for more companies in Sunrise

Search for more companies in Florida



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for BIOHEART INC.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.